Newbridge Financial Services Group, Inc. Chembio Diagnostics, Inc. Transaction History

Newbridge Financial Services Group, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 18, 2023	SELL	$0.25 - $0.45 $1,750 - $3,150	-7,000 Reduced 34.4%	13,350 $5,000
Q1 2022 Apr 26, 2022	SELL	$0.66 - $1.23 $9,718 - $18,111	-14,725 Reduced 41.98%	20,350 $17,000
Q4 2021 Jan 19, 2022	SELL	$1.09 - $2.55 $28,994 - $67,830	-26,600 Reduced 43.13%	35,075 $40,000
Q3 2021 Oct 27, 2021	SELL	$2.06 - $5.34 $26,419 - $68,485	-12,825 Reduced 17.21%	61,675 $154,000
Q2 2021 Sep 07, 2021	SELL	$2.88 - $5.64 $36,532 - $71,543	-12,685 Reduced 14.55%	74,500 $221,000
Q1 2021 Sep 07, 2021	BUY	$3.4 - $7.97 $46,529 - $109,069	13,685 Added 18.62%	87,185 $306,000
Q4 2020 Sep 07, 2021	BUY	$4.11 - $7.51 $302,085 - $551,985	73,500 New	73,500 $349,000

Ticker CEMI
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 30,224,600
Description
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, la...

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.